The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women

Hämmerle, Sibylle P.; Mindeholm, Linda; Launonen, Aino; Kiese, Beate; Loeffler, R. L.; Harfst, E.; Azria, M.; Arnold, M.; John, Markus R.

doi:10.1016/j.bone.2012.01.009

Cited by 40 publications

(21 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Once monthly and once yearly administration of PTH fused to a collagen-binding domain was recently shown to extend its anabolic activity in mice [16,17]. The pharmacokinetic profile of a single dose of a novel oral PTH formulation has been evaluated in healthy postmenopausal women [18].…”

Section: Pth Analogsmentioning

confidence: 99%

New therapeutic targets for osteoporosis: Beyond denosumab

Lim

Clarke

2012

Maturitas

View full text Add to dashboard Cite

Section: Pth Analogsmentioning

confidence: 99%

New therapeutic targets for osteoporosis: Beyond denosumab

Lim

Clarke

2012

Maturitas

View full text Add to dashboard Cite

“…More recent developments relate to the licensing of Eligen® to Novo Nordisk for oral delivery of insulin, GLP-1 (NN9924) and selected structural analogues (e.g. semaglutide [376,377] 5-CNAC has also been evaluated for the oral delivery of sCT [380] and PTH [381] under licence with Nordic Bioscience (Denmark), and partnered with Novartis. Like SNAC, 5-CNAC forms a lipophilic complex with peptides to improve intestinal permeation [382].…”

Section: Whatever the Mode Of Action Snac Was Granted Gras Status Inmentioning

confidence: 99%

Intestinal permeation enhancers for oral peptide delivery

Maher

Mrsny

Brayden

2016

Advanced Drug Delivery Reviews

290

201

View full text Add to dashboard Cite

Publication informationAdvanced Drug Delivery Reviews, (Part B): 277-319 Publisher ElsevierItem record/more information http://hdl.handle.net/10197/7800Publisher's statement þÿ T h i s i s t h e a u t h o r s v e r s i o n o f a w o r k t h a t w a s a c c e p t e d f o r p u b l i c a t i o n i n A d v a n c e d D r u g Delivery Reviews. Changes resulting from the publishing process, such as peer review,

show abstract

“…Once monthly and once yearly administration of PTH fused to a collagen-binding domain fusion protein has been shown to lengthen its anabolic activity in mice [74,75]. The pharmacokinetic profile of a single dose of a novel oral PTH formulation has been evaluated in healthy postmenopausal women [76]. Tablet and transdermal patch formulations are being developed.…”

Section: Pth Analoguesmentioning

confidence: 99%